Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TSHA
#1816
Taysha Gene Therapies, Inc. Common Stock
4.5
3
+0.44%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+0.44%
Monthly Change
-4.43%
6 month change
+51.51%
Year Change
+177.91%
Previous Close
4.5
1
Open
4.5
3
Bid
Ask
Low
4.5
3
High
4.5
3
Volume
115
Markets
US Stock Market
Healthcare
TSHA
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
News
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Taysha doses first patient in pivotal Rett syndrome gene therapy trial
Taysha Gene Therapies stock hits 52-week high at $5.98
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock
Taysha Gene Therapies stock hits 52-week high at 5.51 USD
Goldman Sachs upgrades Taysha Gene Therapies stock rating to Buy
Nagendran Sukumar sells Taysha gene therapies (TSHA) shares for $1.69m
Cantor Fitzgerald maintains Overweight rating on Taysha Gene Therapies stock
Neurogene stock price target raised to $70 from $65 at H.C. Wainwright
Taysha Gene Therapies stock price target raised to $8 at Citizens
Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript